Bayesian Statistics Vague, variable, subjective to boot…

Slides:



Advertisements
Similar presentations
Health and the Web: UK Experience Professor Sir Michael Rawlins Chairman, National Institute for Health and Clinical Excellence And Professor of Clinical.
Advertisements

Risk Analysis Fundamentals and Application Robert L. Griffin International Plant Protection Convention Food and Agriculture Organization of the UN.
NIGB NATIONAL INFORMATION GOVERNANCE BOARD Harry Cayton, Chair, National Information Governance Board.
Patient Involvement Unit Role and Achievements Developing & supporting patient/carer involvement; promoting the patient perspective TAs – workshops for.
Adapting to a changing city - The Equality Agenda Dublin 06.
Technology Appraisal of Medical Devices at NICE – Methods and Practice Mark Sculpher Professor of Health Economics Centre for Health Economics University.
USE OF EVIDENCE IN DECISION MODELS: An appraisal of health technology assessments in the UK Nicola Cooper Centre for Biostatistics & Genetic Epidemiology,
USE OF EVIDENCE IN DECISION MODELS: An appraisal of health technology assessments in the UK Nicola Cooper Centre for Biostatistics & Genetic Epidemiology,
Role of the Quality Manager
West Midlands Academic Health Science Network
Highly Specialised Technologies Evaluations
Bayesian Health Technology Assessment: An Industry Statistician's Perspective John Stevens AstraZeneca R&D Charnwood Bayesian Statistics Focus Team Leader.
A safe space for engagement? Stories from the NICE front line Andrew Dillon Chief Executive National Institute for Health and Clinical Excellence.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Patient Involvement in Pain Guidelines Judy Birch Pain Alliance Europe NHS Evidence Accreditation Advisory Committee.
Lessons Learned in Systems Change Idaho Behavioral Health Transformation Workgroup Forum March 24, 2010 Dave Wanser, Ph.D. Visiting Fellow LBJ School of.
ITEC 370 Lecture 2 Capability Maturity Model. CMM Review Course Engineering Basic components of SE If you had 10 million dollars to invest in a software.
Elicitation Some introductory remarks by Tony O’Hagan.
Cost-Effectiveness Analyses in the UK - Lessons from the National Institute for Clinical Excellence Mark Sculpher Professor of Health Economics Centre.
Structural uncertainty from an economists’ perspective
17/12/2002 CHEBS Launch Seminar CHEBS Activities and Plans Tony O’Hagan Director.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
Continuous Auditing Applications for SAP/R3 Vincent Rykes City of Edmonton.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
Towards an Integrity Standard in the Pharmaceutical Industry IACC Conference, May 27, 2003 Seoul, Korea Dr. Jillian Clare Cohen Assistant Professor, Leslie.
Valuing Medical Technologies The Decision Maker Perspective.
Standards Debate at the Centre for Better Managed Health Care, Cass Business School, City University London, 26 th October Professor Mike Kelly Director.
The National Institute for Clinical Excellence in the UK – Experience and Impact Mark Sculpher Professor of Health Economics Centre for Health Economics.
The Use of Evidence in Economic Decision Models A NICE Perspective Dr Carole Longson Director Centre for Health Technology Evaluation National Institute.
Their contribution to knowledge Morag Heirs. Research Fellow Centre for Reviews and Dissemination University of York PhD student (NIHR funded) Health.
Scientific expert assessment in support of public policies in France The independence issue Personal feedback from two experiences Workshop – London,
©2009 RALPH SNYDERMAN 1 Personalized Health Care: The Foundation of Rational Health Reform Ralph Snyderman, MD Chancellor Emeritus, Duke University James.
NICE Decision Making Dr Katherine Payne North West Genetics Knowledge Park The University of Manchester
NICE: what it is and how it works Professor David Haslam, Chair, NICE 10 th June 2015.
What do patients want from healthcare? Professor David Haslam CBE Chair, NICE Responsible Officers Conference, Brighton.
Shifting resources: disinvestment and re-investment Craig Mitton, PhD Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research.
Agents for Change in partnership with What junior doctors need to know about interactions with industry, transparency, and competing interests Faculty.
Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Results The final report was presented to NICE and published by NICE and WHO. See
1 CHAPTER 2 Decision Making, Systems, Modeling, and Support.
 Learning Objectives:  Understand Meaning and Process of Decision making  Explore factors that affect how decisions are made within organisations 
“What’s in it for us?” NICE Guideline: Safe and Effective use of Medicines (Medicines Optimisation) Erin Whittingham Public Involvement Adviser Public.
FDA PROCESS ANALYTICAL TECHNOLOGY SUB COMMITTEE MEETING 25 TH FEBRUARY 2002 PERSPECTIVE ON PROCESS AND ANALYTICAL VALIDATION Robert S Chisholm.
City University notes AJ Fischer October Nancy’s Questions Q1Different people present material with different cost perspectives? AWith all such.
Operations Research The OR Process. What is OR? It is a Process It assists Decision Makers It has a set of Tools It is applicable in many Situations.
Risk Sharing Schemes Dr Rafiq Hasan Director of Market Access
Operations Research Models and Methods Advanced Operations Research Reference: Operations Research Models and Methods, Operations Research Models and Methods,
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
EVIDENCE-BASED MEDICINE AND PHARMACY 1. Evidence-based medicine 2. Evidence-based pharmacy.
Evidence-Based Dentistry Presenter’s Name. What does EBD mean?
City University notes AJ Fischer October Nancy’s Questions Q1Different people present material with different cost perspectives? AWith all such.
Introduction to NICE Professor David Haslam CBE Chair, NICE Student champion Study Day, January 2015.
Health Technology Assessment
Patient Focused Drug Development An FDA Perspective
Leading Change Leadership as a Contact Sport
Introduction to NICE Professor David Haslam CBE Chair, NICE
Patient Involvement in the HTA Decision Making Process
Making NICE research nicer Involving patients, carers and the public
Learning Aim B: Examine the ethical issues when Providing care and support to meet the individual needs. B1 & B2.
Alejandra Duenas ScHARR
Introduction to NICE Professor David Haslam CBE,
Introduction to NICE Professor David Haslam CBE
HPO Change Conference May 28, 2002
PCORI Research Priorities and Relevant Examples
Dr Peter Groves MD FRCP Consultant Cardiologist
Professor of Health Economics
Dr Rosie Benneyworth Vice-Chair of NICE
Implications and opportunities for the sector?
Presentation transcript:

Bayesian Statistics Vague, variable, subjective to boot…

…and, when used as a basis for decision modelling, helpful for decision makers in NICE technology appraisals Dr Carole Longson Appraisal Programme Director

Attributes of Technology Appraisal Independent advisory committee formulates guidance Transparent and inclusive process Consultation with diverse groups All groups invited to submit evidence

Attributes of Technology Appraisal ‘Inclusive’ evidence base, not just clinical trials Multiple perspectives are often conflicting Decisions are made in the ‘real world’  lack of evidence or conflicting evidence  conflicting views of the same evidence  uncertainty

Evidence Research Evidence Patient Experience Clinical Practice

What matters? Need Size of effect Value of effect Service impact

The Appraisal Challenge Balance the evidence from different inputs Make robust decisions with less than perfect information Ensure process is transparent and decisions are justifiable

Independent technology assessment Patients and carers views and preferences Health professionals opinion Modelling the unknown Manufacturers data Balancing the Evidence

Why we need decision analytic models Uncertainty is the norm in technology appraisal! Good models help decision makers deal with complex and sometimes conflicting evidence

Why we need decision analytic models? To model or not to model?  Yes, no choice for many appraisals Decision analytic models help make better decisions at time t in the absence of perfect information  This is just what the appraisal process needs

Modelling Techniques and Decision Making ‘The good, the bad, the useful and the not so useful ’ We get them all in technology appraisals

"There is nothing more difficult to plan, more doubtful of success, nor more dangerous to manage, than the creation of a new system. For the initiator has the enmity of all who would profit by the preservation of the old institutions, and merely lukewarm defenders in those who should gain by the new ones." Machiavelli The Appraisal Challenge What have we learnt?